CN Patent

CN115003299A — 用于恢复突变体p53功能的方法和化合物

Assigned to PMV Pharmaceuticals Inc · Expires 2022-09-02 · 4y expired

What this patent protects

癌基因和肿瘤抑制基因的突变有助于癌症的发展和进展。本公开描述了用于恢复p53突变体的野生型功能的化合物和方法。本发明的化合物可与突变体p53结合，并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应物的能力。所公开的化合物可用于减少含有p53突变的癌症的进展。

USPTO Abstract

癌基因和肿瘤抑制基因的突变有助于癌症的发展和进展。本公开描述了用于恢复p53突变体的野生型功能的化合物和方法。本发明的化合物可与突变体p53结合，并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应物的能力。所公开的化合物可用于减少含有p53突变的癌症的进展。

Drugs covered by this patent

Patent Metadata

Patent number
CN115003299A
Jurisdiction
CN
Classification
—
Expires
2022-09-02
Drug substance claim
No
Drug product claim
No
Assignee
PMV Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.